Tumour lysis syndrome; new approaches in diagnosis follow up and treatment

Yıl 2013, Cilt: 48 Sayı: 3, 188 - 194, 01.10.2013

Tiraje Celkan Gülen Tüysüz

Öz

Tumor lysis syndrome is a clinical picture which occurs with the lysis of malignant cells and causes metabolic abnormalities that threatens life These metabolic abnormalities are caused by the release of intracellular ions nucleic acids proteins and their metabolites from the instantly degraded tumor cells These rapidly released metabolites can impair the body rsquo;s normal homeostatic mechanism and cause uremia hyperuricemia hyperkalemia and hyperphosphatemia Hypocalcemia which is commonly seen in tumor lysis syndrome is secondary to hyperphosphatemia Generally tumor lysis syndrome occurs after the initiation of chemotherapy but it is rarely observed in fast growing tumours before the treatment due to spontaneous lysis of malignant cells The possibility of tumor lysis syndrome is higher in tumours with high proliferative rates and high tumour burden including Burkitt rsquo;s lymphoma and acute lymphoblastic leukemia The principle of prophylaxis treatment of tumour lysis syndrome includes virgous hydration adequate diuresis control of hyperuricemia with rasburicase or allopurinol regulation of serum electrolytes and dialysis if necessary If the necessary measures are not taken or the clinal situation is not treated properly metabolic abnormalities can cause renal insufficiency cardiac arrhythmia neurologic complications and propably sudden death in patients with cancer Alkalization of urine used to be applied to all patients previously but it is not recommended any longer and this issue is still open to debate In this paper new approaches and innovations in the treatment of tumor lysis syndrome are discussed Turk Arch Ped 2013; 48: 188 194

Anahtar Kelimeler

Allopurinole, rasburicase, tumour lysis syndrome

Tümör lizis sendromu; tanı izlem ve tedavide yeni yaklaşımlar

Öz

Tümör lizis sendromu tümör hücrelerinin hızlı bir şekilde yıkılmasıyla ortaya çıkan ve yaşamı tehdit edebilen metabolik anormalliklerle seyreden klinik bir tablodur Bu metabolik anormallikler ani yıkılan tümör hücrelerinden hücre içi iyon nükleik asit protein ve metabolitlerinin hücre dışı sıvıya sızması sonucunda oluşur Bu hızlı salınan metabolitler vücudun normal hemostatik mekanizmasını bozarak üremi hiperürisemi hiperkalemi ve hiperfosfatemiye neden olabilir Tümör lizis sendromunda sıkça görülen hipokalsemi ise hiperfosfatemiye ikincil olarak ortaya çıkar Tümör lizis sendromu genellikle kemoterapinin başlanmasından sonra görülse de nadiren hızlı büyüyen tümörlerde malin hücrelerin kendiliğinden yıkımı sonucunda tedaviden önce de ortaya çıkabilir Çoğalma hızı fazla tümör yükü yüksek olan Burkitt lenfoma ve akut lenfoblastik lösemi gibi malinitelerde tümör lizis sendromu görülme ihtimali daha yüksektir Tümör lizis sendromu gelişmesini önlemek ve tedavinin esasını yoğun hidrasyon yeterli diürez allopürinol ve veya rasburikaz tedavisi ile hiperüriseminin kontrolü serum elektrolitlerinin düzenlenmesi ve lüzum halinde diyaliz tedavisi oluşturur Gerekli önlemler alınmaz veya oluşan klinik tablo tedavi edilmez ise metabolik anormallikler kanser hastalarında böbrek yetersizliği kardiyak aritmi nörolojik komplikasyon ve muhtemel ani ölüme neden olabilir Daha öncelerde her hastada uygulanan idrarın alkalizasyonu ise son yıllarda pek önerilmemektedir ve bu konu halen tartışmaya açıktır Bu yazıda tümör lizis sendromu ve tedavisi sırasında değişen yaklaşımlar ve yeniliklerden bahsedilecektir.

Anahtar Kelimeler

Allopürinol, rasburikaz, tümör lizis sendromu

Kaynakça

• List AF, Kummet TD, Adams JD, Chun HG. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1990; 89(3): 388-90.
• McCroskey RD, Mosher DF, Spencer CD, Prendergast E, Longo WL. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 1990; 66(2): 246-50.
• Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62(4): 247-50.
• Bose P, Qubaiah O. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther 2011; 36(3): 299-326.
• Frei E 3rd, Bentzel CJ, Rieselbach R, Block JB. Renal complications of neoplastic disease. J Chronic Dis 1963; 16: 757
• Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973; 289(25): 1335-40.
• O’Regan S, Carson S, Chesney RW, Drummond KN Electrolyte and acid-base disturbances in the management of leukemia. Blood 1977; 49(3): 345-53.
• Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am J Medicine 1980; 68(4): 486-91.
• Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978; 62(8): 1117-33.
• Wechsler DS, Kastan MB, Fivush BA. Resolution of nephrocalcinosis associated with tumor lysis syndrome. Pediatr Hematol Oncol 1994;11(1): 115-8.
• Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127(1): 3-11.
• Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995; 9(2): 206Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 1994; 8(3): 351-3.
• Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38(Suppl 4): 4-8.
• Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006; 3(8): 438-47.
• Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26(16): 2767-78.
• Seegmiller JE, Laster L, Howell RR. Biochemistry of uric acid and its relationship to gout. N Engl J Med 1963; 268: 712-6.
• Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 1965; 62: 639-47.
• Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98(5): 1048-54.
• Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008; 80(4): 331-6.
• Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109(2): 292-8.
• Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31(1): 27-8.
• Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA 1965; 193: 1-6.
• Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol 2005; 3(2): 117
• Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007; 4(2): 83-93.
• Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000; 18(8): 1758-63.
• Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991; 109(2): 281-4.
• Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002; 3(4): 433-42.
• Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003; 37(7-8): 1047-54.
• Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010; 36(2): 164-76.
• Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Hematol 2010; 149(4): 578-86.
• Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93(1): 67-74.
• Deger GE, Wagoner RD Peritoneal dialysis in acute uric acid nephropathy. Mayo Clin Proc 1972; 47(3): 189-92.